NVO Stock Price Today (September 2026) — Novo Nordisk A/S Analysis & Key Metrics 2026-09-03
Novo Nordisk A/S (NVO) is trading at $47.51, up 1.58% today (as of September 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $47.17 (-0.7% upside).
- Volatility remains elevated (26.48% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (2.10% YoY) alongside significant competitive pressures.
NVO Stock Analysis: Key Metrics & Valuation (September 2026)
Concise, actionable data for investors
Novo Nordisk A/S - Historical Price & Volume
Market Cap
Enterprise Value: $297.11B
P/E Ratio
Forward P/E: 13.29
Revenue Growth
Year over Year
Analyst Target
+-0.7% upside potential
Key Investor Questions About NVO
What investors need to know before buying
Based on current market data, NVO presents a neutral technical setup with caution warranted fundamentals.
- Technicals say: Neutral (RSI 56.80)
- Fundamentals say: Caution warranted (high leverage concerns)
NVO's growth trajectory depends on its ability to expand within the Drug Manufacturers - General sector while managing margin pressures.
- Future growth will depend on performance in core Drug Manufacturers - General operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for NVO investors include debt exposure and competitive dynamics in the Drug Manufacturers - General industry.
- $140.13B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Drug Manufacturers - General.
52-Week Trading Range
Over the past year, NVO stock traded between $35.12 and $64.16—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 26.48% annualized volatility and β=0.96, the stock exhibits moderate correlation to market moves—making NVO suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Pfizer's Pipeline Strategy Centers on Obesity and Oncology
PFE's pipeline is taking center stage as berobenatide and next-generation oncology drugs aim to drive growth from 2028 and beyond.
Wegovy’s German Debut Opens a New Front for Novo Nordisk (NVO)
Novo Nordisk A/S (NYSE:NVO) has launched its Wegovy weight-loss pill in Germany, making it the first country in the European Union where the oral version of the drug is available. Germany is the EU’s largest pharmaceutical market, so the launch is an important step for Novo as it works to strengthen its position in the […]
HIMS Raises 2026 Revenue Outlook as Q2 Sales Rise 38.2% Despite Loss
HIMS raised its 2026 revenue outlook after Q2 sales jumped 38.2%, but margin contraction and an $86.3 million net loss highlighted growth costs.
European Equities Traded in the US as American Depositary Receipts Track Higher in Wednesday Trading
European equities traded in the US as American depositary receipts were trending higher late Wednesd
Citi flags GLP-1 prescription slowdown at Novo Nordisk, reiterates 'sell'
Citi has reiterated its 'sell' rating on Novo Nordisk (NYSE:NVO), the Danish pharmaceutical group, with a price target of 265 Danish krone against a last close of 292.4 Danish krone. Analyst Emmanuel Papadakis published Citi's weekly IQVIA tracker of Novo's GLP-1 assets, using retail...
Peptide innovator says the drug class is due for a rethink
Karsten Eastman, CEO of Sethera Therapeutics, discusses developments in peptides from cutting-edge innovation to mass consumption.
HIMS Stock Kicks Off September In The Red: FDA’s GLP-1 Alert Steals The Spotlight From Australia Expansion
The FDA reported more than 1,700 adverse events involving compounded Semaglutide and Tirzepatide
Novo Nordisk (CPSE:NOVO B), What Is Behind The Fresh Attention?
Novo Nordisk (CPSE:NOVO B) is back in focus after launching its Wegovy pill in Germany, the first EU market to offer the oral weight loss treatment, putting its GLP-1 obesity ambitions under closer investor scrutiny. The stock has been under pressure despite Novo Nordisk’s obesity pipeline progress, with a 30 day share price return of 4.16%, a year to date share price return decline of 11.05%, and a 1 year total shareholder return down 14.14%. This suggests momentum has faded recently after...
Novo Nordisk Trades Nearly 58% Below GF Value as Wegovy Pill Launches in Germany
Germany becomes the first EU market for oral Wegovy, testing Novo's early lead as Eli Lilly expands.
GSK Stock Down 14% in Six Months: Time to Buy, Hold or Exit?
GSK's shares are down 14% in six months, but strong Specialty Medicines growth and a robust pipeline may support long-term gains.
Explore More Analysis for NVO
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Frequently Asked Questions
Common investor questions about Novo Nordisk A/S
Novo Nordisk A/S (NVO) is currently trading at $47.51. The RSI (14-day) is at 56.8, indicating neutral territory. Wall Street analysts have a consensus "hold" recommendation. The mean analyst price target of $47.17 implies 0.7% downside from current levels. Volatility is moderate at 26.5% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Novo Nordisk A/S (NVO): The trailing P/E ratio is 11.62, which is below the market average of ~20-22, suggesting the stock may be undervalued relative to peers. The forward P/E is 13.29. The PEG ratio is 3.14, above 2.0, suggesting the stock may be overvalued relative to its expected growth. Price-to-Book is 6.10. Price-to-Sales is 0.48. Valuation should be compared to Drug Manufacturers - General industry peers for context, as different sectors trade at different multiples.
Based on 12 analysts covering NVO, the consensus price target is $47.17. This represents a 0.7% downside from the current price of $47.51. The range spans from a low target of $40.21 to a high target of $64.07, reflecting varying levels of optimism among analysts. The consensus recommendation is "hold". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, Novo Nordisk A/S (NVO) pays a dividend with a current yield of approximately 3.79%. The annualized dividend rate is $11.70 per share. The payout ratio is 44.5%, which is conservative and suggests the dividend is well-covered by earnings with room for future increases. The most recent ex-dividend date was 2026-08-17T00:00:00.000Z.
Key risks for Novo Nordisk A/S (NVO) investors include: 1. Moderate volatility (26.5% annualized)—price swings are notable. 2. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 3. Drug Manufacturers - General sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Novo Nordisk A/S's (NVO) current debt and financial health profile: Total debt stands at $140.13B. The debt-to-equity ratio is 63.33, which is moderate and generally manageable for most companies. The current ratio is 0.87, which is below 1.0 and may indicate short-term liquidity concerns. The quick ratio is 0.64. The company holds $44.98B in cash and equivalents. Free cash flow is positive at $37.67B, providing a cushion for debt servicing and shareholder returns.